PTNT — PALATIN TECHNOLOGIES INC

· Health Care · Pharmaceuticals · CIK 911216 ·
Last close
$26.84
Market Cap
52W High
$26.84
52W Low
$25.28
ADV30
3,938
Next earnings
The fund is an exchange-traded fund ("ETF") that seeks to meet its objective by having Corgi Strategies, LLC (the "adviser") actively manage the fund and, under ordinary market conditions, invest at least 80% of its net assets (plus any borrowings for investment purposes) in a portfolio of companies that derive material revenue from intellectual property ("IP") licensing, royalty streams, franchise royalties, or other IP-based monetization arrangements. It is non-diversified.
No quarterly fundamentals indexed for this ticker.

Peers — same industry

TickerNameMarket CapLastDaily %
LLY ELI LILLY & Co $949.47B $1064.74
JNJ JOHNSON & JOHNSON $554.09B $230.18
ABBV AbbVie Inc. $376.54B $213.12
MRK Merck & Co., Inc. $295.69B $119.72
AZN ASTRAZENECA PLC $290.30B $187.19

News headlines (Yahoo Finance, 1h cache)

Palatin Technologies Inc (PTN) Q1 2026 Earnings Call Highlights: Strategic Collaborations and ...
2025-11-13 23:01 · Yahoo
ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight
2025-11-13 22:31 · Yahoo
Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
2025-11-13 12:30 · Yahoo
Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
2025-11-12 17:15 · Yahoo
Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
2025-11-06 13:00 · Yahoo
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering
2025-11-06 12:30 · Yahoo
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim
2025-09-22 11:30 · Yahoo
Boehringer Ingelheim marks retinal disease push with $327m licensing deal
2025-08-18 15:58 · Yahoo
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
2025-08-18 12:05 · Yahoo
Palatin Announces 1-for-50 Reverse Stock Split
2025-08-08 20:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.